Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Thoracic 2Head & Neck 2Dermatologic 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 10Brain Neoplasms 9Glioma 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Neurofibromatosis 1 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Peripheral Nervous System Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Glioma × binimetinib × CNS × Clear all
NCT05355701 2026-06-05

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pfizer

Phase 1 Recruiting
267 enrolled
CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
5 enrolled 15 charts
CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡